5月29日,国家药监局集中发布11款新药上市批件,科创板创新药企表现亮眼,强势占据其中5席。研发管线加速兑现,创新成果密集获批,科创板正成为驱动国内医药创新发展的关键力量。具体来看,此次科创板获批的5款一类新药相关研发成果涉及双抗、融合蛋白、氘代等多个新药研发技术领域,更广泛覆盖了肿瘤、自身免疫性疾病、代谢等众多治疗领域,其中多款为相关领域“国内首款”或“国产首款”,兼具经济效益与社会效益,为护佑...
Source Link5月29日,国家药监局集中发布11款新药上市批件,科创板创新药企表现亮眼,强势占据其中5席。研发管线加速兑现,创新成果密集获批,科创板正成为驱动国内医药创新发展的关键力量。具体来看,此次科创板获批的5款一类新药相关研发成果涉及双抗、融合蛋白、氘代等多个新药研发技术领域,更广泛覆盖了肿瘤、自身免疫性疾病、代谢等众多治疗领域,其中多款为相关领域“国内首款”或“国产首款”,兼具经济效益与社会效益,为护佑...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.